LifeMine Tx appoints CSO and exec VP of CMC

LifeMine Therapeutics, a US start-up searching the fungal biosphere for genetically-encoded small molecules (GEMs), today announced the appointments of Martin Stahl, as chief scientific officer and Louis Plamondon, as executive vice president and head of CMC.

Dr Stahl, who will also lead LifeMine’s operations at its European offices in Basel, Switzerland, joins LifeMine from Swiss pharma giant Roche (ROG: SIX), where he held a variety of scientific leadership roles over 25 years, including positions in medicinal chemistry, immunology, portfolio management and research technologies. Most recently, he served as global head of lead discovery, an organization comprising biophysics, biostructure, biochemistry, cell engineering, assay development and screening capabilities.

Prior to joining LifeMine, Dr Plamondon was senior vice president and head of CMC at Constellation Pharmaceuticals (a MorphoSys company), where he led all pre-development/development activities including production of drug substance and drug product for pre-clinical studies, toxicology studies, clinical studies and preparations for commercialization. Dr Plamondon is a co-inventor and leader for Velcade (bortezomib), the first proteasome inhibitor approved for the treatment of patients with multiple myeloma, and co-inventor for Xerava (eravacycline).